Sample Name
Sample Code
Sample Name
Sample Code
Sample Name
Sample Code
4
BIDU-SW
09888
5
JD HEALTH
06618
| (Q6)Jun 30, 2025 | (Q1)Mar 31, 2025 | (FY)Dec 31, 2024 | (Q6)Jun 30, 2024 | (Q1)Mar 31, 2024 | (FY)Dec 31, 2023 | (Q6)Jun 30, 2023 | (Q1)Mar 31, 2023 | (FY)Dec 31, 2022 | (Q6)Jun 30, 2022 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Turnover | 24.51%35.29B | 25.46%16.65B | 8.65%58.16B | 4.55%28.34B | -4.90%13.27B | 14.54%53.53B | 34.04%27.11B | --13.95B | 52.32%46.74B | 48.30%20.23B |
| Operating income | 24.51%35.29B | 8.65%58.16B | 4.55%28.34B | 14.54%53.53B | 34.04%27.11B | 52.32%46.74B | 48.30%20.23B | |||
| Cost of sales | -21.97%-26.4B | ---- | -7.65%-44.85B | -3.52%-21.64B | ---- | -13.08%-41.66B | -32.24%-20.91B | ---- | -56.89%-36.84B | -53.05%-15.81B |
| Operating expenses | -21.97%-26.4B | -7.65%-44.85B | -3.52%-21.64B | -13.08%-41.66B | -32.24%-20.91B | -56.89%-36.84B | -53.05%-15.81B | |||
| Gross profit | 32.72%8.89B | 12.16%13.31B | 8.01%6.7B | 19.95%11.87B | 40.51%6.2B | 37.43%9.89B | 33.47%4.41B | |||
| Selling expenses | -28.83%-1.81B | ---- | -14.83%-3.05B | -17.52%-1.4B | ---- | -20.91%-2.65B | -28.03%-1.19B | ---- | -2.90%-2.2B | 4.59%-933.3M |
| Administrative expenses | 10.74%-611.51M | ---- | 28.99%-1.42B | 21.87%-685.06M | ---- | 7.20%-2B | 11.09%-876.78M | ---- | 15.12%-2.15B | 12.17%-986.16M |
| Research and development expenses | -14.17%-736.39M | ---- | -8.47%-1.33B | -4.56%-645.02M | ---- | -14.93%-1.23B | -26.72%-616.86M | ---- | -19.52%-1.07B | -21.16%-486.8M |
| Impairment and provision | -633.00%-55.48M | ---- | -352.13%-315.85M | 116.10%10.41M | ---- | 28.86%-69.86M | -486.50%-64.66M | ---- | -156.05%-98.2M | -12.15%-11.03M |
| -Other impairment is provision | -633.00%-55.48M | ---- | -352.13%-315.85M | 116.10%10.41M | ---- | 28.86%-69.86M | -486.50%-64.66M | ---- | -156.05%-98.2M | -12.15%-11.03M |
| Operating interest expense | ---- | ---- | ---- | ---- | ---- | ---- | ---- | ---- | -51.68%-9.1M | -102.28%-4.87M |
| Special items of operating profit | -44.32%-3.58B | ---- | 16.23%-4.26B | 1.47%-2.48B | ---- | -42.40%-5.09B | -60.77%-2.52B | ---- | -49.19%-3.58B | -42.77%-1.57B |
| Operating profit | 40.39%2.1B | 119.78%1.07B | 255.33%2.93B | 60.48%1.49B | -38.74%487.32M | 4.04%824.56M | 118.67%931.36M | 795.45M | 198.17%792.57M | 239.75%425.91M |
| Financing income | -18.29%808.56M | ---- | 0.59%1.96B | 5.67%989.51M | ---- | --1.95B | --936.46M | ---- | ---- | ---- |
| Financing cost | -3.66%-4.17M | ---- | 13.61%-8.19M | 8.34%-4.02M | ---- | ---9.49M | ---4.39M | ---- | ---- | ---- |
| Share of profits of associates | 4.07%-39.15M | ---- | -20.87%-85.53M | -26.74%-40.81M | ---- | 26.87%-70.76M | 33.70%-32.2M | ---- | -2.75%-96.76M | -19.82%-48.57M |
| Earning before tax | 17.40%2.86B | 78.09%4.8B | 33.21%2.44B | 287.08%2.69B | 385.29%1.83B | 177.18%695.81M | 209.28%377.35M | |||
| Tax | 32.75%-272.32M | ---- | -16.20%-639.66M | -50.41%-404.96M | ---- | -76.10%-550.47M | -74.39%-269.23M | ---- | -82.45%-312.58M | -41.76%-154.39M |
| After-tax profit from continuing operations | 27.38%2.59B | 93.99%4.16B | 30.24%2.03B | 459.16%2.14B | 600.58%1.56B | 135.72%383.23M | 149.09%222.96M | |||
| Earning after tax | 27.38%2.59B | 4.58%934.36M | 93.99%4.16B | 30.24%2.03B | 893.43M | 459.16%2.14B | 600.58%1.56B | 135.72%383.23M | 149.09%222.96M | |
| Minority profit | -81.81%-5.1M | ---- | -564.87%-4.83M | -542.27%-2.8M | ---- | -66.74%1.04M | 206.73%634K | ---- | 353.41%3.12M | -163.80%-594K |
| Profit attributable to shareholders | 27.45%2.6B | 94.31%4.16B | 30.48%2.04B | 463.49%2.14B | 598.43%1.56B | 135.41%380.11M | 149.12%223.55M | |||
| Basic earnings per share | 26.15%0.82 | 91.30%1.32 | 30.00%0.65 | 475.00%0.69 | 614.29%0.5 | 134.29%0.12 | 146.67%0.07 | |||
| Diluted earnings per share | 24.62%0.81 | 94.12%1.32 | 32.65%0.65 | 466.67%0.68 | 600.00%0.49 | 134.29%0.12 | 146.67%0.07 | |||
| Currency Unit | CNY | CNY | CNY | CNY | CNY | CNY | CNY | CNY | CNY | CNY |
| Accounting Standards | IAS | IAS | IAS | IAS | IAS | IAS | IAS | IAS | IAS | IAS |
| Audit Opinions | -- | -- | Unqualified Opinion | -- | -- | Unqualified Opinion | -- | -- | Unqualified Opinion | -- |
| Auditor | -- | -- | Deloitte Guan Huang Chen Fang Certified Public Accountants | -- | -- | Deloitte Guan Huang Chen Fang Certified Public Accountants | -- | -- | Deloitte Guan Huang Chen Fang Certified Public Accountants | -- |
FY: Financial Year. Refers to the 10-K file disclosed by the listed company to the SEC.
Q: Quarter. Refers to the 10-Q file disclosed by the listed company to the SEC. Q1, Q2, Q3, and Q4 are quarterly reports each with a span of 3 months; Q6 and Q9 are cumulative reports, with Q6 including 6 months and Q9 9 months.